Exploring the Molecular Mechanisms of Astragalus membranaceus in Treating Pre-eclampsia using Network Pharmacology and Molecular Docking

Background: Pre-eclampsia (PE) is a pregnancy-related complication that has a global prevalence of 3-5% among pregnant women. Objective: The objective of this study is to examine the molecular mechanism underlying the therapeutic effects of Astragalus membranaceus (AE) in the treatment of PE through the application of network pharmacology and molecular docking. Methods: The databases, including TCMSP, Uniprot, Genecards, STRING, and DAVID, and software, including jvenn, Cytoscape, and AutoDock Vina, were used to do the analysis. Results: Sixteen AE-related active ingredients were screened, involving 127 targets, among which the main active ingredients included kaempferol, quercetin, and jaranol, etc. The primary targets of AE for the management of PE encompassed AKT1, CASP3, EGFR, IL1B, IL6, MMP9, PTGS2, TNF, TP53, and VEGFA. The outcomes of the enrichment analysis revealed that AE was predominantly implicated in pathways such as the IL-17 signaling pathway and PI3K-Akt signaling pathway, among others. The molecular docking findings confirmed that the principal active constituents exhibit favorable binding to their central targets. Specifically, the molecular docking results evinced that the primary active ingredients evince robust binding activity towards the core targets. Conclusion: AE has the potential to act synergistically in the management of PE by engaging multiple components, targets, and pathways, thereby establishing a basis for further exploration of its material basis and mechanism of action.